A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

NCT03104413 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

618

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: placebo for risankizumab IV
DRUG: risankizumab SC
DRUG: risankizumab IV

Sponsor

AbbVie